1998 update on antiphospholipid antibodies

Research output: Contribution to journalShort surveypeer-review

11 Scopus citations


The field of antiphospholipid antibodies continues to evolve, with major contributions from both clinical research and laboratory studies. Antiphospholipid antibodies remain one of the more common causes of acquired hypercoagulability, both in patients with systemic lupus erythematosus and in patients who have no known connective tissue disease. In recent years, great progress has been made in identifying the protein targets. In addition, knowledge of the clinical syndrome that we call antiphospholipid antibody syndrome has also progressed. Finally, new insights into treatment continue to be gained from clinical trials.

Original languageEnglish (US)
Pages (from-to)426-430
Number of pages5
JournalCurrent opinion in rheumatology
Issue number5
StatePublished - 1998

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of '1998 update on antiphospholipid antibodies'. Together they form a unique fingerprint.

Cite this